AllerGen NCE Inc.   Report issue

Government Phase 2 Phase 4
Founded: Hamilton Canada (2004)

Organization Overview

First Clinical Trial
2005
NCT00232999
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Alternative names

AllerGen NCE Inc.

Active Ingredients

Drugs in Phase 4 Trials (1)

budesonide (rhinocort) (1 trial)

Drugs in Phase 2 Trials (1)

ivx-0142 (1 trial)

Drugs in Other Trials (3)

albuterol (proventil) (1 trial)

mannitol (Osmitrol) (1 trial)

sodium chloride (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Asthma (Phase 2)

Metabolism, Inborn Errors (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 3
  • # of Trial APIs: 5